Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Videos
Life of a Scientific Poster...
What is LabTube?...PerkinElmer chemagic 360...MicroCal Differential Scanning Calorimet...

Featured Products
Provance® Prepacked Protein A Columns
Provance® Prepacked Protein A Columns
Sartobind STIC® Salt-Tolerant Membrane Chromatography
Sartobind STIC® Salt-Tolerant Membrane Chromatography

Webcasts
A Potentially Scalable Method for the Harvesting of hMSCs from Microcarriers: Initial ResultsA Potentially Scalable Method for the Harvesting of hMSCs from Microcarriers: Initial Results
Qasim Rafiq, Loughbrough University, speaking at Advances in Cellular Assays & Cell Culture 2014
Magneto-plasmonic Nanoparticle Platform for Capture, Separation and Enumeration of Rare CellsMagneto-plasmonic Nanoparticle Platform for Capture, Separation and Enumeration of Rare Cells
Konstantin Sokolov, The University of Texas at Austin, speaking at Nanomedicine 2014.

Market Reports
Immunoassay Auto Trends 2014
HTStec

This report comprehensively documents current practices and preferences in immunoassays and to understand future user requirements, particularly with respect to immunoassay automation.
Label-Free Binding Analysis Trends 2014
HTStec

This market report summarizes the results of HTStec’s 4th global web-based benchmarking survey on label-free (LF) binding analysis carried out in July 2014. The study was initiated by HTStec as part of its regular (every 2 years) tracking of this life science marketplace. The questionnaire was compiled to address the needs and interests of the LF binding analysis vendor community.
Pharmaceutical Key Trends 2011: Biosimilar Market Overview
Datamonitor plc

Biosimilars were estimated to have generated approximately $200m in sales during the twelve months to March 2010. Going forward, with branded biologics worth $55bn set to face patent expiry between 2011 and 2015, this presents a major opportunity for companies looking to enter the biosimilars market.
Preclinical Development of Monoclonal Antibodies and Related Biologicals: Emerging technologies and new therapeutic candidates
Business Insights

This report explains what monoclonal antibodies are, and why large pharmaceutical companies are investing so heavily both in developing such drugs internally and acquiring monoclonal antibody candidates from others. More than 80 popular and emerging technologies are named, explained and illustrated with original full-color diagrams.
Innovations in Combating Infectious Diseases: Opportunities in therapeutics and diagnostics through application of proteomics, genomics, nanotechnology, and novel sources of lead generation
Business Insights

This report makes a detailed and comprehensive analysis of the cutting edge of research aiming to reveal how bacteria, viruses, fungi, and prions infect and affect their hosts. It also assesses the new technologies and techniques that are being used to design and develop the anti-infective drugs and diagnostic methods of the 21st century.
Cancer Vaccines & Circulating Tumor Cells (CTCs) 2011 Report
Select Biosciences Ltd

This market report from Select Biosciences presents a comprehensive industry analysis of the cancer vaccines space as well as that of the emerging circulating tumor cells (CTCs) space. These two areas are evolving and expanding driven by the greater emphasis on personalized medicine especially in the cancer/oncology space.
Biosimilars and Biobetters: Positioning for a New Market
Select Biosciences Ltd

As regulatory frameworks for biosimilars development begin to take shape worldwide, there are growing opportunities for generics companies to enter the biologics market, a segment which is uniquely driven by unmet needs, commands premium prices, and continues to outperform the global pharma market.
Novel Antibodies & Therapeutic Proteins: Technological Challenges & Future Prospects
Select Biosciences Ltd

This innovative & analytical report can be used to assess market trends & appraise the potential of new antibodies & therapeutic proteins. It provides perspective to gain an in-depth understanding of the marketplace, players, products & leading technologies driving the field.
Scientific News
Madison Researchers Begin Work on Zika Virus
Work will start with basic questions about Zika virus infection.
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Business News
Velesco Pharma Opens New Analytical Testing Laboratory
Company has announced that it has opened new CGMP-compliant analytical testing laboratory for development of vaccines and biologics with improved stability and preserved potency.
Qualicaps® Acquires Genix Industria Farmaceutica Ltda
Company has announced that acquisition allows the company to effectively expand its global presence from operating sites in Japan, Spain, Romania, Canada and the USA, to include Brazil.
Regeneron Joins Human Vaccines Project
Regeneron Pharmaceuticals has announced that it has joined the Human Vaccines Project, a public-private partnership to help discover and develop new vaccines and immunotherapies for infectious diseases and cancer.
Transgene and ABL Announce the Acquisition
Company has announced the acquisition of its production asset in Illkirch by ABL Europe.
VBI, GSK Collaborate
VBI Vaccines has entered into a research collaboration with GlaxoSmithKline Biologicals SA (“GSK”) to evaluate VBI’s LPV™ Platform. VBI’s LPV Platform is a proprietary formulation and process that enables the development of vaccines and biologics with improved stability and preserved potency.
RedHill Biopharma, Fraunhofer Institute Launch Collaboration
Collaboration to focus on the evaluation of RedHill’s Phase II-stage oncology drug candidate, RP101.
Mersana Therapeutics, Takeda Expand Partnership
Mersana to receive $40 million upfront, $20 million upon IND clearance and up to $20 million in equity investment.
Affinivax Secures Funding for Pneumococcal Vaccine
Company achieves key milestones and additional $2.5 million from the Gates Foundation.
Lonza to Build Capabilities for Drug Product Development
Company to Develop Drug Product Services for Customers by building its capabilities step-wise over the coming years.
ImmunoGen, Merck Establish Collaboration
ImmunoGen, a biotechnology company that develops novel anticancer therapeutics using its ADC technology, and Merck, known as MSD outside the United States and Canada, announced have that they have entered into a clinical research collaboration.

Events
Flow Chemistry Europe 2016 - 6
16 Feb 2016
Flow Chemistry Europe 2016 - 6 ...
More information
Downstream Processing World Co
23 Feb 2016
Downstream Processing World Co ...
More information
8th Annual AsiaTIDES
24 Feb 2016
8th Annual AsiaTIDES ...
More information
LYOTALK 2016 Asia-Pacific larg
25 Feb 2016
LYOTALK 2016 Asia-Pacific larg ...
More information

ePosters
Better Cell-Based Assays for Anti-CTLA-4, Anti-PD-1/PD-L1, and Bispecific Immunotherapy Drug Studies
Promega Corporation

Here we report the development of a panel of robust reporter assays to measure the potencies for biologics in immunotherapy. These assays reflect mode of action and can serve as valuable tools in immunotherapy drug development and discovery.
Development of a Robust Reporter-based T cell Activation Assay for Therapeutic Biologics in Immunotherapy
Promega Corporation

Jurkat T-cells stably expressing luciferase reporter driven by IL2 promoter or NFAT-RE, are used as effector cells. Tumor cell lines endogenously expressing cancer antigen are used as antigen presenting cells (APC). By co-cultivating the two cell lines in the presence of CD3 bispecific antibody, TCR/CD3 is activated in Jurkat effector cells. Luciferase activity is up regulated through IL-2 promoter or NFAT-RE activation.
Reporter Bioassays to Assess Therapeutic Antibodies for Immunotherapy Programs
Promega Corporation

Immunotherapy, also called biologic therapy or biotherapy, stimulates certain parts of the immune system to fight diseases such as cancer. Important drug targets in immunotherapy include: Co-inhibitory receptors, such as PD-1/PD-L1, CTLA-4, LAG3, Tim3; and co-stimulatory receptors, such as GITR, CD40, OX40, 4-1BB.
Current approaches to assaying these targets are cumbersome and variable. Here we offer an improved in vitro bioassay approach.
Automated in-gel digestion on a commercial autosampler directly coupled to nanoLC-MS/MS
University of Bern, Department of Clinical Research, Proteomics & Mass Spectrometry Core Facility, Bern, Switzerland : CTC Analytics AG, Zwingen, Switzerland

SDS-PAGE separates protein samples from LC-MS incompatible contaminations, and is frequently used to fractionate proteins of entire proteomes. One disadvantage is that gel lanes have to be cut into many slices, followed by in-gel digestion of proteins and extraction of peptides. The number of these gel slices goes into the hundreds, rendering this process very repetitive and prone to mistakes and errors during sample handling. Automation reduces such risks and improves reproducibility.
Automated sample preparation workflows for quantitative proteomics applications
1Max Delbrück Center for Molecular Medicine in the Helmholtz Association, MDC, Berlin, Germany; 2CTC Analytics, Zwingen, Switzerland; 3Axel Semrau GmbH, Sprockhövel, Germany

Mass spectrometry based proteomics requires large scale identification of peptides, and depends upon efficient sample preparation. Recently, we presented two automated protein-digestion setups, in-solution and in-gel digestion. We extended these techniques by implementing dimethyl labelling (DML). Furthermore, we established an automated phospho-peptide (PP) enrichment procedure in a 96-well formate, generating phospho-proteomic data in very short time.
Characterization of Protein and Protein Aggregates using Temperature-controlled Hollow-Fiber Flow-FFF
Posntova

Reproducibilty Improvements in Field Flow Fractionation can be achieved on two fronts. Instrument design and control, the system used in for this poster is does not require flow controllers or switching valves and there for produces the same conditions in every case. Fractionater design, the design of the cartridges used in this poster maintain excellent conditions to maintain constant pressure at the membrane removing unwanted effects of sale relaxation above the membrane s
Specificity of highly potent miRNA inhibitors
Dharmacon part of GE Healthcare

Specificity of highly potent miRNA inhibitors
HOMOGENEOUS ADCs BEARING TWO DIFFERENT PAYLOADS SHOW STRONG SYNERGY IN TUMOR KILLING
Dophen Biomed and TUBE Pharmaceuticals GmbH

We presented a one-pot reaction to prepare site-specific ADCs using available mABs on hand without re-engineering. We have identified a novel non-cleavable linker, which increases not only ADC stability, but also potency. We also demonstrate synergy in cancer cell killing of hybrid ADC loaded with two different toxins
Toward a Comprehensive Bottom-up and Top-down Analysis of the NIST Reference Monoclonal Antibody
1Protein Metrics Inc., San Carlos, CA USA, 2National Institute of Standards and Technology (NIST), Gaithersburg, MD USA

Development of ADC and other therapeutic proteins require careful characterization of sequence, post-translational modifications, sequence variants, and degradants. In this study, a NIST mAb interim reference material was analyzed by new bioinformatics tools (Byonic™, Byologic®, and Byomap™) allowing one to efficiently identify and quantify modifications down to trace levels.
Enabling Epigenetics Studies from HTS to SAR : A Novel HTRF® Platform to Identify and Characterize Reader Domain Inhibitors
1Cisbio Bioassays Codolet, France | 2CRCM, CNRS UMR7258, INSERM U1068, AMU UM105, Institut Paoli-Calmettes, Marseille, France | 3AFMB, UMR7257, Univ. Aix Marseille-CNR

Discover a novel HTRF platform to identify and characterize the vast variety of epigenetic binding domain.

Application Notes
Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies
Malvern Instruments Limited

The rapid growth of the therapeutic antibody market has increased the interest in modeling of the antibody structure and in understanding the factors that affect the function and the stability of antibodies.
Identification of Insulin Oligomeric States Using SEC-MALS
Wyatt Technology Corporation

This application note shows how the combination of column chromatography (SEC/GPC) with MALS, DLS and RI detection can be applied as a powerful tool to identify monomers, dimers, hexamers and higher aggregates of insulin.
Charge and Interaction Analysis for Predicting Antibody Formulation Stability
Wyatt Technology Corporation

Colloidal stability is a key solution property of a biotherapeutic formulations, indicative of long-term stability. As it is readily measured over much shorter time scales than long-term stability testing or even accelerated testing regimens, measurements of colloidal stability are often utilized in the course of formulation work to screen out poorly behaved conditions.
The Diffusion Interaction Parameter (kD) as an Indicator of Colloidal and Thermal Stability
Wyatt Technology Corporation

This experiment demonstrates that thermal and colloidal stability of proteins, two indicators of propensity to aggregate, as well as actual aggregation states, are all determined simultaneously during the screening process with dynamic light scattering (DLS) tools in order to rank the effectiveness of candidates and formulation conditions.
Accelerating the Development of Optimized Therapeutic Protein Formulations using Differential Scanning Calorimetry
Malvern Instruments Limited

DSC data is useful in predicting the stability of a protein in solution. The Tm indicates thermostability, and Tm determination in different formulations is an approximate measure of the susceptibility to aggregation and other irreversible changes at lower temperatures.
Differentiation and characterization of subvisible particulates in therapeutic protein products
Malvern Instruments Limited

The formation of protein aggregates is a particular concern for parenteral administration biopharmaceuticals due to the potential for increased immunogenicity.
An Introduction to Proteins in 30 minutes
Malvern Instruments Limited

In the biotechnology industry, the majority of research is directed towards characterizing the structure and function of proteins. New methods are continually being developed to accomplish this.
Performing ADCC Reporter Bioassay with an Environmentally Controlled Microplate Reader
Tecan Group Ltd.

The Promega ADCC Reporter Bioassay provides effector and target cells in frozen, thaw-and-use format, removing the need for isolating or culturing cells in order to perform the assay. Reporter induction requires a six-hour to overnight incubation in a standard cell culture incubator. The CO2 and temperature control features of the Tecan Infinite® 200 PRO with GCM allow the assay induction to be performed without the requirement for a cell culture incubator.
Tag-lite® two-cell assay: a valuable tool for protein drug discovery
Tecan Group Ltd.

Antibodies are central mediators of the immune system, IgG being the most dominant. Binding of IgG/antigen complexes to membrane-bound Fc? receptors triggers a cellular immune response. Alterations in the Fc portion of the antibody by introducing mutations can lead to complete abolition of Fc? receptor binding. This describes the development of a cellbased TR-FRET assay to determine the simultaneous binding of an antibody to its antigen and huFc?RIIIa present on different cells.
Protein Purification Workflow Development Using Bio-Rad's NCO' Chromatography System
Bio-Rad Laboratories

High purity protein is a common requirement for biochemical and structural studies. A common approach is to recombinantly express an affinity-tagged version of the protein of interest. This is, however, not always a viable option. This application note discusses protein purification workflow development for untagged proteins and introduce a new indicator of method performance, the purity quotient difference.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!